These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25397540)

  • 1. Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study.
    Gazaignes S; Resche-Rigon M; Yang C; Gatey C; Munier AL; Desseaux K; Rozenbaum W; Molina JM
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19796. PubMed ID: 25397540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.
    Gazaignes S; Resche-Rigon M; Gatey C; Yang C; Denis B; Fonsart J; Desseaux K; Guionie M; Rozenbaum W; Delaugerre C; Molina JM
    Antivir Ther; 2016; 21(4):329-36. PubMed ID: 26566057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.
    Stellbrink HJ; Antinori A; Pozniak A; Flamm J; Bredeek F; Patel K; Garner W; Piontkowsky D
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19793. PubMed ID: 25397537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.
    Pérez-Hernández IA; Palacios R; Mayorga M; González-Doménech CM; Castaño M; Rivero A; Del Arco A; Lozano F; Santos J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19795. PubMed ID: 25397539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ruxrungtham K; Putcharoen O
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19740. PubMed ID: 25397485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
    Phongsamart W; Jantarabenjakul W; Chantaratin S; Anugulruengkitt S; Suntarattiwong P; Sirikutt P; Kosalaraksa P; Maleesatharn A; Chokephaibulkit K
    J Int AIDS Soc; 2022 Jan; 25(1):e25862. PubMed ID: 35001501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
    Porter DP; Toma J; Tan Y; Solberg O; Cai S; Kulkarni R; Andreatta K; Lie Y; Chuck SK; Palella F; Miller MD; White KL
    HIV Clin Trials; 2016 Feb; 17(1):29-37. PubMed ID: 26899540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
    Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
    Vingerhoets J; Rimsky L; Van Eygen V; Nijs S; Vanveggel S; Boven K; Picchio G
    Antivir Ther; 2013; 18(2):253-6. PubMed ID: 22951490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.
    Bernaud C; Khatchatourian L; Rodallec A; Hall N; Perre P; Morrier M; Pineau S; Jovelin T; André-Garnier E; Raffi F; Allavena C
    Infect Dis (Lond); 2016 Oct; 48(10):754-9. PubMed ID: 27389932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
    Lombaard J; Ssali F; Thanyawee P; Fourie J; Vanveggel S; Linthicum C; Van Eygen V; Van Solingen-Ristea R
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0091621. PubMed ID: 34871089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
    Chounta V; Snedecor SJ; Wu S; Van de Velde N
    BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
    Wilkin A; Pozniak AL; Morales-Ramirez J; Lupo SH; Santoscoy M; Grinsztejn B; Ruxrungtham K; Rimsky LT; Vanveggel S; Boven K;
    AIDS Res Hum Retroviruses; 2012 May; 28(5):437-46. PubMed ID: 21902621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
    Gatechompol S; Avihingsanon A; Apornpong T; Han WM; Kerr SJ; Ruxrungtham K
    AIDS Res Ther; 2019 Apr; 16(1):7. PubMed ID: 30953533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
    Molina JM; Ene L; Cahn P; Fätkenheuer G; Van Wijngaerden E; Lombaard J; Zakharova N; Van Eygen V; Vanveggel S; Van Solingen-Ristea R
    Antivir Ther; 2021 Nov; 26(6-8):95-105. PubMed ID: 35485339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia.
    Thamrongwonglert P; Chetchotisakd P; Anunnatsiri S; Mootsikapun P
    HIV Clin Trials; 2016 Feb; 17(1):12-6. PubMed ID: 26739573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.